PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial ...
PDS Biotech announces updated VERSATILE-002 Phase 2 trial results: Median Overall Survival of 30 months, Objective Response Rate of 36%, and Disease Control Rate of 77% for Versamune® HPV + KEYTRUDA® in HPV16-positive recurrent/metastatic HNSCC. Plans to initiate VERSATILE-003 Phase 3 trial this year.
Reference News
PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial ...
PDS Biotech announces updated VERSATILE-002 Phase 2 trial results: Median Overall Survival of 30 months, Objective Response Rate of 36%, and Disease Control Rate of 77% for Versamune® HPV + KEYTRUDA® in HPV16-positive recurrent/metastatic HNSCC. Plans to initiate VERSATILE-003 Phase 3 trial this year.